NewcelX NCEL

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders with unmet medical needs. The company's lead compound mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist in a proprietary extended-release formulation, is being developed for the treatment of narcolepsy, idiopathic hypersomnia, and potentially attention deficit hyperactivity disorder. NewcelX Ltd aims to address critical treatment gaps by developing new chemical entities from known molecules and repurposing previously approved molecules with established safety profiles.

NewcelX Ltd generates revenue through the development and potential commercialization of its product candidates, primarily Quilience and Nolazol, which contain mazindol as the active ingredient in a proprietary controlled-release formulation. The company does not currently have commercial products on the market and relies on financing activities such as registered direct offerings and support agreements to fund its clinical development programs. Revenue generation is expected to begin upon regulatory approval and market launch of its lead product candidates for narcolepsy and attention deficit hyperactivity disorder.

The company operates through the following segments:.

NewcelX Ltd operates in a competitive landscape within the central nervous system therapeutics industry, particularly in the narcolepsy and attention deficit hyperactivity disorder markets. Key competitors for narcolepsy include Jazz Pharmaceuticals with sodium oxybate products and Harmony Biosciences with pitolisant. For attention deficit hyperactivity disorder, the company competes with established stimulant medications such as Vyvanse and other amphetamine or methylphenidate-based treatments. NewcelX Ltd believes its competitive advantages stem from the unique dual mechanism of action of mazindol, which combines triple monoamine reuptake inhibition with partial orexin-2 receptor agonism, offering potential benefits in efficacy, safety, and tolerability compared to existing therapies.

NewcelX Ltd serves patients suffering from rare and complex central nervous system disorders, including those with narcolepsy, idiopathic hypersomnia, and attention deficit hyperactivity disorder. The company's product candidates are intended for adult and potentially pediatric populations diagnosed with these conditions, aiming to address unmet medical needs in underserved patient communities.